Navigation Links
New Research Released at AHA Confirms Itamar's PAT Technology to Diagnose Early Cardiovascular Disease

Four presentations at AHA, including one from the Framingham Heart Study, link PAT signal with several cardio-vascular conditions and risk factors as

technology gains broader acceptance

ORLANDO, Fla., Nov. 4 /PRNewswire/ -- Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.

Presentation of several research works at the American Heart Association's Scientific Sessions, including one by the Framingham Heart Study, as well as numerous other recently published studies, support the emerging of the Endo- PAT as a significant tool in the prevention and management of cardiovascular disease.

Based on the new studies, combined with earlier numerous successful trials of the Endo-PAT at the Mayo Clinic, Harvard University and other academic medical centers, Itamar Medical is now ready to make Endo-PAT Technology available to clinicians beyond the research environment and into the general medical community.

The Endo-PAT, developed by Itamar Medical, is the only FDA approved non- invasive device that reliably detects a pathology called endothelial dysfunction. The condition refers to an impairment of the endothelial layer, which is the inner tissue lining of the blood vessels and is emerging as a key precursor for the development of atherosclerosis -- a major component in cardiac disease, the nation's number one killer.

The non-invasive Endo-PAT device, based on PAT technology, measures subtle but significant vaso-motion changes through a small thimble-like probe placed over a person's index finger. Tests administered with the Endo-PAT provide clinicians and researchers an effective tool for the detection of endothelial dysfunction. Early detection has the potential to reduce the medical and cost burden of cardiovascular disease. Valuable diagnostic information can be obtained from the Endo-PAT at a fraction of the cost of other established approaches which can only be administered by a skilled technician and even then are too operator dependent.

In addition to the data from the Framingham Heart Study, that showed in a large population base study an association between the Endo-PAT results and several risk factors, three other oral presentations from Britain and Sweden showed the relevancy of endothelial function assessment with the Endo-PAT in other conditions in children and adults.

About Itamar Medical

Itamar Medical Ltd., established in 1997, is a public (TASE: ITMR) medical technology company that developed the proprietary PAT(TM) (Peripheral Arterial Tone) signal technology and applications. The PAT signal is a non-invasive "window" to the cardiovascular system and the autonomic nervous system. For more information, visit

SOURCE Itamar Medical Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. More Research Required For COPD
8. Researchers identify the early makers of Neonatal Sepsis
9. OHSU Researchers Announce New Discovery
10. Skin Cancer Research To Go Global
11. Researchers Identify Gene Connected To Bipolar Disorder
Post Your Comments:
(Date:10/13/2015)... ... 13, 2015 , ... T-System and Centegra Health System, a ... department visits per year, today announced the successful and rapid deployment of EV™, ... and financial outcomes. , In less than four days, Centegra Hospitals ...
(Date:10/13/2015)... ... ... Tempe Dental Care, a leading Tempe dentists’ office, celebrates offering gentle, pain free sedation ... than 5 years. A leading cause of emergency room visits, school absences, and missed ... , Sedation dentistry provides an anxiety-free dental experience with safe and ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
(Date:10/13/2015)... ... October 13, 2015 , ... According to an ESPN ... orbital fracture when a teammate accidentally elbowed him in the left eye during the ... injury is just one of a series of setbacks, including a knee injury that ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... Saye as the newest professional to introduce the latest development, ThermiVa® temperature controlled ... as a leading professional in Obstetrics and Gynecology and a pioneer in the ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 13, 2015  Synapse Biomedical Inc. ( ) ... (PAS) studying the use of the NeuRx ® ... enroll patients. the United States ... market-approved criteria. The PAS study group met their initial ... study has since expanded the enrollment target to 150 ...
(Date:10/13/2015)... 2015  SeraCare Life Sciences, a leading partner to ... company,s precision medicine business unit has launched its second ... next-generation sequencing (NGS)-based tumor profiling assays.  The Seraseq TM ... mixture of mutations in key oncogenes and tumor suppressor ... , but is offered at five additional allele frequencies. ...
(Date:10/13/2015)... , Oct. 13 2015 ... the addition of the "US & ... 16 Countries (2010-2021)" report to their ... announced the addition of the "US ... - 16 Countries (2010-2021)" report to ...
Breaking Medicine Technology: